In mid-2024, WeightWatchers International Inc. (WeightWatchers), the dominant player in the weight loss industry, announced mixed results for its foray into GLP-1 medications via its WeightWatchers Clinic offering. Chief executive officer Sima Sistani had orchestrated a major pivot for the over 60-year-old company by embracing weight loss drugs that were disrupting the company’s traditional business of weight loss through controlled intake and peer counselling. Sistani had stated a goal of 160,000 to 180,000 Clinic subscribers by the end of 2024. However, the company had met only half of their stated subscriber goal midway through the year. Sistani had to come up with a plan to reach the goal amid declining revenues and significant losses.
看看哪些人也有訂購？